Veselibas Centrs 4 SIA

At Veselibas Centrs 4 SIA in Riga, clinical research in cardiovascular disease and lipid disorders focuses on reducing major heart and stroke risks while improving long-term treatment outcomes.

• Studies in atrial fibrillation are evaluating ways to prevent stroke and systemic embolism.
• Research in hypercholesterolemia is testing new approaches to lower LDL cholesterol and reach individual treatment targets.
• Trials in people at high cardiovascular risk are examining whether new therapies can reduce heart attack and ischemic stroke.
• Work in chronic heart failure and HFrEF is assessing treatments that may improve symptoms and lower hospitalization risk.

These studies are designed to test whether newer therapies can better protect patients with serious cardiovascular conditions and related metabolic risk factors.

Research at this hospital/clinic includes several studies in inflammatory skin disease and immune-mediated conditions, with a strong focus on symptom control and long-term safety.

• Trials in moderate-to-severe plaque psoriasis are evaluating new treatments to improve skin clearance and maintain response over time.
• Studies in atopic dermatitis and prurigo nodularis are testing therapies aimed at reducing itch and improving overall disease control.
• Immune-focused research is also examining whether new medicines can provide better symptom relief for chronic inflammatory skin disorders.

Overall, this area of research is centered on finding more effective and better-tolerated options for patients living with persistent immune-related skin diseases.

Clinical trials in digestive system disease at Veselibas Centrs 4 SIA are concentrated on ulcerative colitis, a chronic inflammatory condition of the bowel.

• Researchers are studying whether new therapies can help bring about clinical remission in adults with active disease.
• The trials are also aimed at improving symptom control for people with moderately to severely active ulcerative colitis.

This work supports the development of more effective treatment options for patients with ongoing intestinal inflammation.

In the area of musculoskeletal disease, the site is involved in research on post-menopausal osteoporosis, with attention to bone strength and fracture prevention.

• These studies are evaluating whether new therapies can improve bone mineral density.
• The research also looks at how well treatments maintain their effect on markers of bone turnover.

The goal is to support better care for women at risk of bone loss and related complications.